A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX Made With the Varicella Enhanced Process (VEP)

Trial Profile

A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX Made With the Varicella Enhanced Process (VEP)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 01 Mar 2013 Planned end date changed from 1 May 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Planned initiation date changed from 1 Jun 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top